Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN (NYSE: QGEN) has announced the opening of a new data center in Melbourne, Australia, expanding its global bioinformatics infrastructure to eight facilities worldwide. The new center will serve the Australia/Asia-Pacific region, including Australia, New Zealand, New Guinea, and surrounding islands.
The Melbourne facility joins QIAGEN's existing network of data centers in the United States, United Kingdom, Denmark, Turkey, South Korea, Japan, and China. It will provide in-country data hosting services, enabling genomic testing laboratories to comply with Australian privacy and health data regulations while securely managing sensitive data.
QIAGEN Digital Insights currently serves 90,000 users worldwide and has profiled 4 million patient cases over its 25-year history in the industry. The expansion demonstrates QIAGEN's commitment to supporting clinical next-generation sequencing (NGS) testing services and ensuring data security, compliance, and operational excellence globally.
QIAGEN reported solid Q4 2024 performance with net sales of $521 million (+2% actual rates, +4% CER core growth). Q4 highlights include net sales of $525 million CER exceeding the $520 million outlook and adjusted diluted EPS of $0.61 surpassing guidance. The adjusted operating income margin improved to 30.6%, up 2.6 percentage points from Q4 2023.
Key products QIAstat-Dx, QuantiFERON, and QIAcuity maintained double-digit growth. For full-year 2024, the company exceeded sales and adjusted EPS outlook, with free cash flow increasing 63% to $506 million. The 2025 outlook projects about 4% CER sales growth (5% CER core sales growth) and adjusted diluted EPS of at least $2.28 CER, targeting adjusted operating income margin improvement of at least 150 basis points.
The company returned approximately $300 million to shareholders in January through a synthetic share repurchase.
QIAGEN (NYSE: QGEN) has secured a favorable ruling from the German Federal Patent Court in a patent dispute against SD Biosensor, validating a key patent for its QuantiFERON technology. The decision upholds QIAGEN's intellectual property rights for the German portion of European Patent EP 3 421 997, which protects important innovations in tuberculosis detection.
The ruling reinforces QIAGEN's QuantiFERON-TB Gold Plus position as the global standard for latent TB testing. The technology is part of a portfolio of over 120 patents and is recommended by major health organizations including WHO and CDC. The test offers superior accuracy and reliability compared to traditional skin testing methods for identifying individuals at risk of developing active tuberculosis.
QIAGEN has announced details for a synthetic share repurchase plan to return up to $300 million to shareholders, combining a direct capital repayment with a reverse stock split. The plan follows a similar $300 million repurchase completed in early 2024, totaling $600 million of the company's commitment to return at least $1 billion to shareholders by 2028.
The repurchase terms include consolidating every 36 issued shares into 35 shares, reducing approximately 6.2 million shares from the 223.9 million shares outstanding at end-2024. Shareholders will receive $1.26 per pre-split share. The last trading day for pre-split shares is planned for January 28, 2025, with consolidated shares beginning trading on January 29, 2025, on both NYSE and Frankfurt Stock Exchange under existing ticker symbols.
QIAGEN N.V. (NYSE: QGEN) has announced its schedule for the release of Q4 2024 financial results. The press release will be issued on Wednesday, February 5, after 22:05 Frankfurt time (21:05 London/16:05 New York). A conference call will follow on Thursday, February 6, at 16:00 Frankfurt time (15:00 London/10:00 New York).
Participants can join the conference call through three options: registering for a callback connection, dialing in directly using provided international numbers, or accessing the audio webcast. The conference ID for phone dial-in is 9237018. A replay of the conference call will be made available through a provided webcast link.
QIAGEN (NYSE: QGEN) has announced plans to return up to $300 million to shareholders through a synthetic share repurchase, combining a direct capital repayment with a reverse stock split. This follows a similar $300 million repurchase completed in early 2024, totaling $600 million of the company's commitment to return at least $1 billion to shareholders by the end of 2028 (absent M&A opportunities).
The synthetic repurchase, scheduled for completion in late January 2025, will be executed through a three-step process: increasing the par value of common shares, implementing a reverse stock split, and reducing the par value back to the original level with direct capital repayment to shareholders. This approach aims to deliver faster returns compared to traditional open-market repurchases while enhancing earnings per share (EPS) through reduction in outstanding shares.
QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity Digital PCR system, enabling simultaneous analysis of up to 12 targets from a single biological sample, more than doubling its previous capability of five targets. This upgrade is achieved through the new QIAcuity Software 3.1 and the launch of the QIAcuity High Multiplex Probe PCR Kit, requiring no hardware changes to existing instruments.
The system has shown strong market adoption with over 2,700 cumulative placements by end of 2024 and citations in more than 550 publications. The enhancement makes lab work more efficient by reducing time, reagent consumption, and sample material usage. The platform integrates partitioning, thermocycling, and imaging into a streamlined workflow, reducing processing times from six to two hours.
The QIAcuity platform is available in one-, four-, and eight-plate versions to accommodate different laboratory sizes and throughput requirements. The technology is particularly valuable for applications in translational research, microbiome analysis, pathogen detection, and cell and gene therapy development.
QIAGEN (NYSE: QGEN) has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, marking the first in a series of gastrointestinal panel tests. The panel covers five key causes of gastrointestinal illness recommended by the IDSA, including four bacteria and Norovirus.
This clearance makes QIAGEN the first company to offer both comprehensive and targeted syndromic gastrointestinal panels, enhancing diagnostic flexibility for healthcare providers. The test delivers results in about one hour with minimal hands-on time.
A second version covering five bacterial pathogens is planned for FDA submission. Additionally, QIAGEN plans to submit its higher-capacity QIAstat-Dx Rise instrument for FDA clearance in early 2025, which can process up to 160 tests daily using eight Analytical Modules.
QIAGEN has partnered with Genomics England to support the Generation Study, a groundbreaking initiative to sequence genomes of 100,000 newborns in England. The study, launched in October 2024, will screen for over 200 treatable conditions that affect approximately 3,000 babies annually in the UK.
Through its Clinical Knowledge Base, QIAGEN will be the exclusive provider of clinically relevant variant content for genes included in the point-of-care sequencing test. The company's knowledge base combines expert manual curation with machine extraction, containing biological content from more than 40 databases and has been used to analyze over 4 million NGS patient test cases globally.
The initiative aims to enable earlier diagnosis and treatment of rare conditions like Metachromatic leukodystrophy (MLD), potentially improving health outcomes for thousands of families through early intervention.
QIAGEN has launched Ingenuity Pathway Analysis (IPA) Interpret, an AI-powered extension designed to enhance the interpretation of complex biological data. The new feature builds upon IPA's extensively curated knowledge base, which has over 50,000 citations, to help researchers understand gene involvement in diseases, biological processes, and drug responses.
IPA Interpret automatically analyzes gene expression datasets, identifying key biological processes, pathways, and networks, presenting results in a shareable web-page format. The tool combines human expertise with AI and Natural Language Processing to ensure reliable data analysis and causal relationships. This launch follows QIAGEN's recent AI initiatives, including an AI-driven biomedical knowledgebase release in early 2024 and AI enhancements to QIAGEN Clinical Insight Interpret in late 2023.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
